The Promise and Limitations of Neoadjuvant Immune-Checkpoint Blockade in Resectable Non–Small Cell Lung Cancer

The landscape of neoadjuvant immune-checkpoint blockade for resectable non–small cell lung cancer has become an exciting area of clinical and translational exploration. Cascone and colleagues present a platform study of one cycle of novel immunomodulatory agents prior to surgical resection, offering a unique opportunity to perform translational biomarker studies, though many questions remain regarding the ultimate application to a broader patient population.

See related article by Cascone et al., p. 2394 (1).